SHC Stock Analysis: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$15.34
0.07 (0.43%)
▲
5d:
-0.62%
30d:
-5.92%
90d:
-10.27%
BUY
HIGH Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 05, 2026
0d
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SHC appears deeply undervalued. Market expects -4.6% annual earnings decline despite 175% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: SHC appears deeply undervalued. Market expects -4.6% annual earnings decline despite 175% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.07
Based on 6.5% avg growth
INTRINSIC VALUE TODAY
$14.95
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $15.34, which is considered slightly low relative to its 30-day fair value range of $15.36 to $15.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.4) compared to its historical average (16.6). Remarkably, the market is currently pricing in an annual earnings decline of 4.6% over the next few years. This pessimistic expectation contrasts with the company's recent 175.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SHC is in a strong downtrend. Immediate support is located at $14.26, while resistance sits at $16.17.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.12 (+31.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong downtrend. Immediate support is located at $14.26, while resistance sits at $16.17.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.12 (+31.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$15.36 -
$15.91
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.8% below Wall St target ($20.12)
Trading Range Analysis
30-Day Trading Range
$15.36 -
$15.91
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$14.26
Resistance Level
$16.17
Current Trend
Strong Downtrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.42
Wall Street Target
$20.13
(+31.8%)
Revenue Growth (YoY)
10.0%
Earnings Growth (YoY)
175.4%
Profit Margin
9.9%
Valuation Discount vs History
-4.6% cheaper
PE vs Historical
14.4 vs 16.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.6%
(market-implied from PE analysis)
1-Year Target
$14.57
(-5%)
2-Year Target
$13.90
(-9%)
3-Year Target
$13.26
(-13%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$15.27
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 9.0%)
$30.24
(+98%)
Base:
(SPY PE: 14.4, Growth: 9.0%)
$19.75
(+29%)
Bear:
(PE: 12.3, Growth: 9.0%)
$16.79
(+10%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 37.78 | Current EPS (TTM): $0.41
Bull Case
$34.08
(+123%)
Analyst growth 100.0%, PE expands to 41.6
Base Case
$30.98
(+103%)
Market implied 100.0%, PE stable at 37.8
Bear Case
$10.53
(-31%)
Severe decline -20.0%, PE contracts to 32.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.4 to 16.6
Stabilization Target:
$17.58
(+15.1%)
PE Expansion Potential:
+15.1%
Share & Embed Analysis
Last updated: May 18, 2026 2:39 PM ET
Data refreshes hourly during market hours. Next update: 3:39 PM
Data refreshes hourly during market hours. Next update: 3:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Gtcr Investment Xi Llc
SELL
10000000 shares
2026-03-06
Michael B Jr. Petras
SELL
315896 shares
2025-12-08
Michael B Jr. Petras
SELL
434104 shares
2025-12-08
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$613 | 53 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$248 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$131 | 61 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 53 HOLD |
